Diabetes News

Tag: HbA1c

Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial

September 24th 2022

The association of eTIR with complications is largely explained by its correlation with HbA1c. HbA1c, not eTIR or continuous glucose monitoring TIR, remains the preferred outcome in clinical studies of type 1 diabetes complications

The Relationships Between Glycated Hemoglobin and Bone Turnover Markers in Patients with Type 2 Diabetes but No Diabetic Nephropathy

June 9th 2022

An increase in HbA1c is associated with gradual decreases in the circulating concentrations of 25OHD and OC (International Journal of General Medicine)

Variability in Test Interval Is Linked to Glycated Haemoglobin (HbA1c) Trajectory over Time

May 16th 2022

These findings indicate that the consistency of testing interval, not the just number of tests/year, is important in maintaining diabetes control, especially in those with moderately raised HbA1c levels (Journal of Diabetes Research)

Is HbA1c a valid surrogate for mortality in type 2 diabetes? Evidence from a meta-analysis of randomized trials

May 10th 2022

Based on the results of more than 200 randomized trials, HbA1c is not a valid surrogate marker for all-cause mortality in people with type 2 diabetes (Acta Diabetologica)

Reductions in HbA1c with Flash Glucose Monitoring Are Sustained for up to 24 Months: A Meta-Analysis of 75 Real-World Observational Studies

April 27th 2022

Meta-analysis of RWE confirms that using the FreeStyle Libre system is associated with significant reductions in HbA1c for adults with T1DM or with T2DM. Reductions are greater for people with higher baseline HbA1c and are sustained for 24 and 12 months in T1DM and TD2M respectively (Diabetes Therapy)

Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study

April 6th 2022

A prespecified sensitivity analysis of protocol-compliant participants showed a significant difference in HbA1c concentration between groups. No new safety signals were identified and there was a low risk of severe hypoglycaemia (The Lancet Diabetes & Endocrinology)

Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme

April 5th 2022

Oral semaglutide demonstrated consistently greater HbA1c and body weight reductions across a range of patient characteristics, with greater HbA1c reductions seen at higher baseline HbA1c levels (Diabetes, Obesity and Metabolism)

Joint 30-year HbA1c and lipid trajectories and mortality in type 1 diabetes

February 18th 2022

These results suggest there is a subgroup with type 1 diabetes who, despite poor glycemic control, has a relatively good prognosis, perhaps related to good Non-HDLc (Diabetes Research and Clinical Practice)

HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target

January 27th 2022

These findings suggest that HbA1c variability may provide additional information for an optimized management of diabetes, particularly in people within the target of HbA1c (Cardiovascular Diabetology)

Glycemic Control and Risk of Sepsis and Subsequent Mortality in Type 2 Diabetes

January 20th 2022

In a nationwide cohort of individuals with type 2 diabetes, we found a U-shaped association between HbA1c and sepsis and a fourfold increased risk of death among those developing sepsis (Diabetes Care)

Relationship between glycosylated hemoglobin and iron deficiency anemia: A common but overlooked problem

January 7th 2022

Our study has shown conclusivly that IDA is related to increased HbA1c concentrations and HbA1c decreases significantly following treatment with iron. IDA should be considered before making any decisions regarding diagnosis or treatment according to HbA1c (Primary Care Diabetes)

Association of glycated hemoglobin A1c levels with cardiovascular outcomes in the general population: results from the BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) consortium

November 17th 2021

Elevated HbA1c levels were associated with cardiovascular disease incidence and overall mortality in participants without diabetes underlining the importance of HbA1c levels in the overall population (Cardiovascular Diabetology)

Relationship Between Time-in-Range, HbA1c, and the Glucose Management Indicator in Pregnancies Complicated by Type 1 Diabetes

November 5th 2021

GMI may better reflect glycemic control than HbA1c in early pregnancy (Diabetes Technology and Therapeutics)

Real-world screening for diabetes in early pregnancy: Improved screening uptake using universal glycated haemoglobin

October 24th 2021

Universal early pregnancy HbA1c appears feasible as an early screening test for women at risk of hyperglycaemia in pregnancy and would expedite and increase screening in Aboriginal women compared to an early OGTT (Primary Care Diabetes)

Dissociation of Glycated Albumin and HbA1c Is Associated With a Decline of Glomerular Filtration Rate as Evaluated by Inulin Clearance

October 21st 2021

In conclusion, GA and HbA1c are dissociated by GFR reduction in patients with glycemic disorder, and eGFR and HbA1c may not provide an accurate measure of the risk of DKD. Thus, care is needed in evaluating glycemic control using HbA1c in patients with kidney dysfunction (Diabetes Care)

Optimal glucose, HbA1c, glucose-HbA1c ratio and stress-hyperglycaemia ratio cut-off values for predicting 1-year mortality in diabetic and non-diabetic acute myocardial infarction patients

October 20th 2021

SHR was the most consistent independent predictor of 1-year all-cause mortality in both diabetic and non-diabetic STEMI, whereas glucose was the best predictor in NSTEMI patients (Cardiovascular Diabetology)

Glucose Regulation Beyond HbA1c in Type 2 Diabetes Treated With Insulin: Real-World Evidence From the DIALECT-2 Cohort

October 8th 2021

In this study, a high HbA1c did not reduce the occurrence of nocturnal hypoglycemia, and low HbA1c was not associated with the highest TIR. Optimal personalization of glycemic control requires the use of newer tools, including CGM-derived parameters (Diabetes Care)

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study

September 28th 2021

Patients receiving OW semaglutide experienced statistically significant and clinically relevant reductions from baseline in HbA1c and body weight. These results are in line with those of the SUSTAIN RCTs and support the use of OW semaglutide in routine clinical practice in adults with T2D in the UK (Diabetes Therapy)

Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88

September 22nd 2021

The glycemic legacy effects seen in type 2 diabetes are explained largely by historical HbA_1c values having a greater impact than recent values on clinical outcomes. Early detection of diabetes and intensive glucose control from the time of diagnosis is essential to maximize reduction of the long-term risk of glycemic complications (Diabetes Care)

Advances in GLP-1 treatment: focus on oral semaglutide

September 16th 2021

Oral semaglutide effectively reduces glycated hemoglobin (HbA1c) levels and body weight in a broad spectrum of patients with T2D and shows cardiovascular safety (Diabetology & Metabolic Syndrome)